Skip to main content

Table 1 sCD73 activity in metastatic melanoma patients

From: Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab

  n SCD73 activity pmol/min/mg protein [median (range)] P valuea
Gender
 Male 21 26.7 (0.0–255.3) 0.007
 Female 16 0.0 (0.0–75.8)
Age (years)
 < 62 18 21.9 (0.0–93.7) 0.16
 ≥ 62 19 6.4 (0.0–255.3)
BRAF status
 Wt 19 16.5 (0.0–90.9) 0.99
 Mutated 13 13.9 (0.0–255.3)
Brain mets
 Yes 7 16.0 (0.0–90.9) 0.84
 No 27 13.9 (0.0–255.3)
LDH (IU/L)
 < 480 17 7.2 (0.0–90.9) 0.11
 > 480 19 25.2 (0.0–255.3)
N of previous therapy line
 2 24 10.0 (0.0–93.7) 0.28
 > 2 12 19.5 (0.0–255.3)
  1. WT wild-type, mets: metastasis, LDH lactate dehydrogenase, IU/L International Units per Liter, N number
  2. aMann–Whitney U test